MedCentralSemaglutide Fails to Meet Desired Endpoints for Alzheimer’s

Semaglutide failed to slow cognitive decline in Alzheimer’s trials enrolling 3,808 participants despite improving disease biomarkers. The 156-week Evoke and Evoke+ Phase 3 trials tested oral semaglutide (14 mg) against placebo in early-stage AD patients—biomarkers moved favorably, but no clinically meaningful benefit emerged on primary cognitive endpoints.

🧠 CLINICAL CONSIDERATIONS

• Biomarker improvements without cognitive benefit challenge treatment selection for patients seeking Alzheimer’s therapies beyond approved anti-amyloid antibodies
• GLP-1 RAs demonstrated protective effects in diabetes populations but mechanism did not translate to meaningful cognitive preservation in symptomatic AD patients
• Results reinforce disease complexity requiring scrutiny of trial design factors: dosing, duration, brain penetration, and participant selection criteria
• Trial discontinuation after 104 weeks suggests insufficient target engagement despite semaglutide’s metabolic and neuroinflammatory effects in brain tissue

🎯 PRACTICE APPLICATIONS

• Document that oral semaglutide lacks evidence for Alzheimer’s treatment when patients request GLP-1 RAs for cognitive protection
• Continue standard AD therapies with approved anti-amyloid agents for appropriate candidates despite safety profile concerns
• Monitor subgroup analyses at CTAD December 2025 and AD/PD conferences March 2026 for population-specific responses
• Counsel diabetic patients that metabolic benefits do not extend to proven dementia prevention in symptomatic disease

More on GLP-1s